全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Acute Toxicity of Three Dimensional Conformal Concurrent Chemoradiation with Dose Optimization for External Beam Radiation in Carcinoma Cervix—A Prospective Study

DOI: 10.4236/ijmpcero.2016.53022, PP. 204-211

Keywords: 3D Conformal, Dose Optimization, Acute Radiation Toxicity

Full-Text   Cite this paper   Add to My Lib

Abstract:

Aim: To prospectively evaluate the acute toxicity of 3D conformal radiotherapy with dose optimization in patients with carcinoma cervix. Materials and Methods: Carcinoma cervix patients stage IIB to IIIB (n = 30) treated during November 2011 to May 2013 at the institution with 3D conformal chemo-radiation were included in the study. They received weekly Cisplatin 40 mg/m2 for a maximum of 5 cycles. They received 46 Gy/23 fractions, 5 fractions per week of external beam radiation. In these patients dose optimization was done in order to achieve a tumor maximum dose (Dmax) around 105%. Various techniques were used for dose optimization which included the use of sub fields, adjusting the weightages, using wedges and the use of mixed energies. EBRT (External Beam Radiotherapy) was followed by two fractions of high dose rate intracavitary brachytherapy of 9 Gy each. Acute RTOG toxicity was assessed weekly during EBRT and 1 week post EBRT. Results: The median age of the patients was 45 (range: 30 - 55 years). All the patients completed EBRT; 63.3% of the patients received all 5 cycles of chemotherapy while 26.6% of the patients received 4 cycles of chemotherapy and 10% of the patients received 3 cycles of chemotherapy. The most predominant toxicity seen was GI toxicity, diarrhea being the most common GI toxicity followed by vomiting. Neutropenia was the most common hematological toxicity. Most patients had grade 0 and grade 1 toxicity. None of the patients had grade 4 toxicity while few had grade 2 and 3 toxicity. Conclusion: 3D conformal concurrent chemo radiotherapy with Dmaxaround 105% reduces acute RTOG toxicity particularly grade 3 and 4 and improves patient compliance for concurrent chemo-radiotherapy.

References

[1]  Parkin, D.M., Bray, F., Ferlay, J. and Pisani, P. (2001) Estimating the World Cancer Burden: Globocan 2000. International Journal of Cancer, 94, 153-156.
[2]  Green, J., Kirwan, J., Tierney, J., Vale, C., Symonds, P., Fresco, L., et al. (2005) Concomitant Chemotherapy and Radiation Therapy for Cancer of the Uterine Cervix. Cochrane Database of Systematic Reviews, 3, Article ID: CD002225. http://dx.doi.org/10.1002/14651858.cd002225.pub2
[3]  Chan, P., Yeo, I., Perkins, G., Fyles, A. and Milosevic, M. (2006) Dosimetric Comparison of Intensity-Modulated, Conformal, and Four-Field Pelvic Radiotherapy Boost Plans for Gynecologic Cancer: A Retrospective Planning Study. Radiation Oncology, 1, 1-13. http://dx.doi.org/10.1186/1748-717X-1-1
[4]  Forrest, J., Presutti, J., Davidson, M., Hamilton, P., Kiss, A. and Thomas, G. (2012) A Dosimetric Planning Study Comparing Intensity-Modulated Radiotherapy with Four-Field Conformal Pelvic Radiotherapy for the Definitive Treatment of Cervical Carcinoma. Clinical Oncology, 24, 63-70. http://dx.doi.org/10.1016/j.clon.2011.06.008
[5]  Gerstner, N., Wachter, S., Knocke, T.H., Fellner, C., Wambersie, A. and Pötter, R. (1999). The Benefit of Beam’s Eye view Based 3D Treatment Planning for Cervical Cancer. Radiotherapy & Oncology, 51, 71-78.
http://dx.doi.org/10.1016/s0167-8140(99)00038-9
[6]  Radiation Therapy Oncology Group (RTOG). https://www.rtog.org/CoreLab/ContouringAtlases/GYN.aspx
[7]  ICRU-62 (1999) ICRU Report 62 International Commission on Radiation Units and Measurements. Bethesda, MD.
[8]  Macdonald, D.M., Lin, L.L., Biehl, K., Mutic, S., Nantz, R. and Grigsby, P.W. (2008) Combined Intensity-Modulated Radiation Therapy and Brachytherapy in the Treatment of Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics, 71, 618-624. http://dx.doi.org/10.1016/j.ijrobp.2008.02.014
[9]  Green, J., Kirwan, J., Tierney, J., Vale, C., Symonds, P., Fresco, L., et al. (2005) Concomitant Chemotherapy and Radiation Therapy for Cancer of the Uterine Cervix. Cochrane database of Systematic Reviews, 3, Article ID: CD002225. http://dx.doi.org/10.1002/14651858.cd002225.pub2
[10]  Keys, H.M., Bundy, B.N. and Stehman, F.B. (1999) Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical Carcinoma. The New England Journal of Medicine, 340, 1154-1161. http://dx.doi.org/10.1056/NEJM199904153401503
[11]  Pearcey, R., Brundage, M., Drouin, P., Jeffrey, J., Johnston, D., Lukka, H., et al. (2002) Phase III Trial Comparing Radical Radiotherapy with and without Cisplatin Chemotherapy in Patients with Advanced Squamous Cell Cancer of the Cervix. Journal of Clinical Oncology, 20, 966-972. http://dx.doi.org/10.1200/JCO.20.4.966
[12]  Rose, P.G., Bundy, B.N., Watkins, E.B., Thigpen, J.T., Deppe, G., Maiman, M.A., et al. (1999) Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer. The New England Journal of Medicine, 340, 1144-1153. http://dx.doi.org/10.1056/NEJM199904153401502

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133